Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03760952
Other study ID # IMA-SCREENING
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 26, 2019
Est. completion date November 15, 2022

Study information

Verified date February 2024
Source Immatics US, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This screening study will identify HLA molecular subtype positive and tumor antigen target(s) positive patients who may be eligible for enrollment into Immatics clinical studies. This screening study is intended for patients with advanced and/or metastatic solid cancers. No treatment intervention will occur as part of this screening study.


Description:

The purpose of this screening study is to identify human leukocyte antigen (HLA) molecular subtype positive and tumor antigen target(s) positive patients. No treatment intervention will occur as part of this screening study. After diagnosis of advanced and/or solid metastatic cancers, patients will be tested for HLA molecular subtype positivity. Patients that are HLA molecular subtype positive are then assessed to determine if their tumor antigen target(s) is positive (biopsy screening). Fresh tumor tissue obtained by a biopsy for this screening study will be required. If the patient is undergoing a surgical procedure directed towards tumor or palliative treatment (e.g., a resection, debulking surgery, etc.) and has consented to the study, then fresh tissue may be collected during the procedure to avoid the patient being subjected to another biopsy. Tumor antigen targets in fresh tumor samples will be determined by an in vitro diagnostic (IVD) assay. Therefore, any remaining tumor specimens may be used for exploratory biomarker analyses and validation studies for regulatory approval. Immatics is conducting clinical studies which target patients with advanced and/or metastatic solid cancers. Patients who are HLA subtype phenotype positive and whose tumors express one or more of the tumor antigen targets of interest may be eligible for ongoing clinical studies of adoptive cell therapy (ACT).


Recruitment information / eligibility

Status Completed
Enrollment 242
Est. completion date November 15, 2022
Est. primary completion date November 15, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed an Informed Consent Form (ICF) 2. Patients = 18 years of age 3. Patients with confirmed advanced and/or metastatic solid tumors. 4. For liver cancer patients, the diagnosis must be confirmed - Pathological diagnosis of liver cancer based on biopsy/resection is required - For patients without pathological diagnosis, an imaging technique obtained by computed tomography (CT) scan or magnetic resonance imaging (MRI) is needed. 5. Eastern Cooperative Oncology Group (ECOG) performance status = 0-1 6. Life expectancy > 6 months 7. There is no limitation for prior anti-cancer treatments 8. HLA molecular phenotype positive. 9. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)1.1 10. At least one lesion considered accessible for biopsy unless fresh tumor tissue is being collected during a surgical procedure directed towards tumor treatment or palliative therapy or the patient has uterine cancer (including endometrial cancer or uterine carcinosarcoma) or melanoma 11. Patient has adequate pulmonary function 12. Acceptable organ and marrow function 13. Acceptable coagulation status 14. Adequate hepatic function 15. Acceptable levels of serum creatinine 16. For liver cancer patients only, Child-Pugh score of < 6 Exclusion Criteria: 1. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years 2. Patients with primary central nervous system (CNS)/brain tumors 3. Patients whose tumors have very low expression of tumor antigen targets such as kidney chromophobe, thyroid carcinoma, and prostate adenocarcinoma 4. Patients who are pregnant or are breastfeeding 5. Patients with serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents 6. Patients with prior stem cell transplantation or solid organ transplantation 7. Any condition contraindicating leukapheresis 8. Patients with any of the following cardiac conditions: uncontrolled hypertension despite optimal therapy, uncontrolled angina, ventricular arrhythmias, congestive heart failure, baseline left ventricular ejection fraction = 50%, prior or current cardiomyopathy, atrial fibrillation with heart rate > 100 bpm, unstable ischemic heart disease 9. Patients with active diverticulitis, intra-abdominal abscess, or GI obstruction 10. Patients with active pneumonitis 11. Patients with active (uncontrolled/untreated) brain metastases NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis. 12. History of hypersensitivity on fludarabine (FLU), cyclophosphamide (CY), or interleukin (IL)-2 13. History of current immunodeficiency disease or prior treatment compromising immune function at the discretion of the investigator. 14. Patients with Grade 3 or Grade 4 immune-related toxicities related to checkpoint inhibitors or patients requiring corticosteroid treatment (= 10 mg/day prednisone or equivalent dose). 15. Patients with bleeding diathesis or coagulopathy 16. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with patient's safety 17. HIV infection, active hepatitis B or C infection. History of treated hepatitis B or C is permitted if the viral load is undetectable per qPCR and/or nucleic acid testing

Study Design


Locations

Country Name City State
United States University of Chicago Chicago Illinois
United States Oncology Consultants Houston Texas
United States Columbia University Medical Center New York New York
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Immatics US, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of antigen target expression in solid tumors 3 years
Other Comparison of antigen target expression in fresh and FFPE tumor samples 3 years
Primary Frequency of patients with protocol-specified HLA subtype 3 years
Primary Frequency of patients with expression of analyzed tumor antigen targets 3 years
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2